NCT06626516 2025-11-28
Tebentafusp-tebn With LDT in Metastatic UM
Thomas Jefferson University
Phase 1/2 Recruiting
Clinical Trials
22 trialsNCT02275416 2024-12-16
Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma
Ultimovacs ASA
Phase 1/2 Completed
NCT03538314 2024-08-22
UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma
Ultimovacs ASA
Phase 1 Completed
NCT00071981 2023-06-28
Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT04703426 2023-05-22
Sargramostim (GM-CSF) + PD-1
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT02009397 2021-11-22
A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients
University of Louisville
Phase 1/2 Completed
NCT01826864 2020-07-27
Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma
Jonsson Comprehensive Cancer Center
Phase 3 Withdrawn
NCT01363206 2020-03-19
GIPI
Northern California Melanoma Center
Phase 2 Completed
NCT02451488 2020-02-10
Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma
Mayo Clinic
Phase 4 Completed
NCT01875653 2019-05-10
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Lisata Therapeutics, Inc.
Phase 3 Terminated
NCT00470015 2019-02-19
Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma
Mayo Clinic
Phase 1 Completed
NCT03282188 2018-05-04
REO13 Melanoma With of Without GM-CSF
University of Leeds
Phase 1/2 Withdrawn
NCT00471471 2017-06-22
Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
University of Pittsburgh
Phase 1 Completed
NCT00631072 2017-06-09
In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT00948480 2016-07-15
DCVaccineMel
Hoag Memorial Hospital Presbyterian
Phase 2 Completed
NCT00089219 2014-11-20
Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma
University of Virginia
Phase 1/2 Completed
NCT00085423 2013-04-10
Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT00512889 2013-03-01
Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma
Dana-Farber Cancer Institute
Phase 1 Completed
NCT00006243 2013-01-25
Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma
National Cancer Institute (NCI)
Phase NA Completed
NCT00616564 2012-05-03
Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma
Mt. Sinai Medical Center, Miami
Phase 2 Completed
NCT00912574 2009-06-03
MEL38
University of Virginia
Phase NA Completed
NCT00350597 2006-07-11
GM-CSF as Adjuvant Therapy of Melanoma
Northern California Melanoma Center
Phase 2 Completed